戻る Agenda
Patient Preferences – The Science of Tomorrow
Session Chair(s)
Conny Berlin, MS
IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology
Novartis Pharma AG, Switzerland
The science of patient preferences is evolving rapidly. Close interactions between patients, researchers and decision makers show how a new approach to support medicinal development can be established.
Speaker(s)
Rare Disease Patients in Dialogue with Regulators and HTA Bodies: Patient Views
Rocco Falchetto, PHD
International Porphyria Patient Network, Switzerland
President
IMI PREFER: What Do We Want to Learn from Case Studies?
Ardine De Wit
University Medical Center Utrecht, Netherlands
Associate Professor of HTA
Preference Elicitation in at Risk Individuals of Rheumatoid Arthritis – an IMI PREFER study
Christine Radawski, MPH
Eli Lilly, United States
Benefit Risk Scientist